NewVest Reaches $180M for Third Private Markets Index Fund
- NewVest PE50 2024 is the second private equity index fund managed by NewVest and the third in its growing suite of passively constructed index products
- Significant capital committed by one of the largest global private markets asset managers through a strategic partnership with NewVest
- Seeks to provide efficient access to 50 of the largest PE funds raising capital in 2024
- NewVest is a pioneer of private markets index funds that invest directly in underlying funds, offering investors a no management fee option at the NewVest level
"We believe there is great potential for a passive approach in private markets to deliver some of the benefits seen in public markets, such as lower costs, greater diversification, and reduced volatility of expected returns over the long term," said
NewVest PE50 2024 seeks to provide investors with efficient access to 50 of the largest private equity funds for the 2024 vintage period, which are collectively targeting over
With its inaugural NewVest PE50 2023 and private debt-focused NewVest PD50 2023, which collectively raised
About NewVest
NewVest, the private markets index manager, offers innovative, passively constructed index funds designed to provide investors with diversified exposure to some of the largest private market funds globally. By effectively allowing investors to "buy the market" in individual private market asset classes (such as private equity and private debt) for a single vintage period, NewVest seeks to simplify and streamline private markets investing for a broad range of investors.
NewVest Management, L.P. is an SEC Registered Investment Advisor. For more information, please visit https://www.newvest.com.
Media Contact:
+971 50 197 5819
[email protected]
View original content:https://www.prnewswire.com/news-releases/newvest-reaches-180m-for-third-private-markets-index-fund-302295360.html
SOURCE NewVest
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agroz Inc. renames shares and adopts dual-class structure
- Takeda psoriasis drug shows skin clearance in Phase 3 trials
- EMA backs orphan drug status for Vanda's imsidolimab in rare skin disease
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share